Status: Not yet recruiting
A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer
This study aims to evaluate the efficacy and safety of the concurrent combination therapy of S 531011 + fruquintinib or S 531011 + fruquintinib + pembrolizumab in patients with MSS/pMMR colorectal cancer.
Participants needed: 68
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: National Cancer Center Hospital EastUpdated: May 18, 2026
Eligibility criteria
Patients with histologically confirmed unresectable adenocarcinoma of the colon... [+12]
Prior treatment with fruquintinib for metastatic colorectal cancer. [+17]